RWP
MREO

RWA Wealth Partners’s Mereo BioPharma MREO Stock Holding History

RWA Wealth Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,550
Closed -$45.2K – 573
2024
Q2 		$45.2K Buy
+12,550
New +$40.7K ﹤0.01% 540

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RWA Wealth Partners's MREO Position: Q3 2024 in Review

RWA Wealth Partners sold out of Mereo BioPharma (MREO) in Q3 2024, closing a stake of 12,550 shares — an estimated $45.2K sold.

RWA Wealth Partners first reported a position in MREO in Q2 2024 and held it in 1 quarter. The position peaked at $45.2K in Q2 2024. 77 funds tracked by Wall St. Rank hold MREO as of Q3 2024.

  • RWA Wealth Partners reported no remaining Mereo BioPharma position as of Q3 2024 after selling out during the quarter.
  • RWA Wealth Partners sold 12,550 Mereo BioPharma shares in Q3 2024, an estimated $45.2K.
  • RWA Wealth Partners first reported a position in Mereo BioPharma in Q2 2024 and held it in 1 quarter.
  • RWA Wealth Partners's Mereo BioPharma position peaked at $45.2K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2024.

Based on RWA Wealth Partners's 13F filing for Q3 2024, filed 8 Nov 2024.